【摘要】 目的 探讨针对晚期结肠癌患者应用新型抗肿瘤药物贝伐珠单抗+化疗方案治疗的价值及作用机制。方法随机选取2019年1月—2021年3月该院收治的70例晚期结肠癌患者，按随机数表法分为观察组与对照组，每组35例。对照组应用常规mFOLFOX6化疗方案治疗6个月，观察组在对照组的基础上加用贝伐珠单抗治疗6个月，对比两组临床疗效、肿瘤标志物水平与免疫指标变化、不良反应情况。结果 观察组总有效率94.29%显著高于对照组77.14%，差异有统计学意义（χ~2=4.200,P<0.05）；治疗后两组患者癌胚抗原、糖链抗原19-9水平均较治疗前降低，而观察组治疗后癌胚抗原、糖链抗原19-9水平分别为（15.62±1.52）μg/L、（30.12±2.41）k U/mL，均显著低于对照组（26.23±2.48）μg/L、（43.36±2.89）k U/mL，差异有统计学意义（t=21.579、20.816,P<0.05）；两组治疗后白蛋白（ALB）水平均较治疗前降低，观察组为（33.21±3.74）g/L，对照组为（33.06±3.71）g/L，但组间比较差异无统计学意义（t=0.168,P>0.05）；两组患者治疗期间不良反应分级比较差异无统计学意义（P>0.05）。结论 应用新型抗肿瘤药物贝伐珠单抗联合化疗方案治疗晚期结肠癌的效果满意，其机制同降低肿瘤标志物水平有关，且药物对免疫功能影响小及不增加不良反应发生情况。更多还原

【Abstract】 Objective To investigate the value and mechanism of the new antitumor drug bevacizumab + chemotherapy regimen for advanced colon cancer patients. Methods A total of 70 patients with advanced colon cancer who were treated from January 2019 to March 2021 were randomly selected and divided into an observation group and a control group according to the random number table method, with 35 cases in each group. The control group was treated with conventional mFOLFOX6 chemotherapy for 6 months. The observation group was treated with bevacizumab for 6 months on the basis of the control group, and the clinical efficacy, tumor marker levels and immune index changes, and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 94.29%, which was significantly higher than that of the control group 77.14%, and the difference was statistically significant(χ~2=4.200, P <0.05). After treatment, the levels of carcinoembryonic antigen and sugar chain antigen 19-9 in the two groups were significantly lower than those before treatment, the levels of carcinoembryonic antigen and sugar chain antigen 19-9 in the observation group were(15.62±1.52) μg/L and(30.12±2.41) kU/mL, which were significantly lower than those in the control group(26.23±2.48)μg/L,(43.36±2.89) kU/mL,the difference was statistically significant(t=21.579, 20.816, P<0.05); the level of albumin(ALB) in the two groups after treatment was both lower than those before treatment,(33.21±3.74) g/L in the observation group,(33.06±3.71)g/L in the control group, but there was no statistically significant difference between the groups(t=0.168, P>0.05);there was no statistically significant difference in the grades of adverse reactions between the two groups during treatment(P>0.05). Conclusion The new antitumor drug bevacizumab combined with chemotherapy has a satisfactory effect in the treatment of advanced colon cancer, and its mechanism is related to the reduction of tumor marker levels. And the drug has little effect on immune function and does not increase the occurrence of toxic and side effects.更多还原